NO20080487L - Rekominant interferona2 (IFNa2) mutanter - Google Patents

Rekominant interferona2 (IFNa2) mutanter

Info

Publication number
NO20080487L
NO20080487L NO20080487A NO20080487A NO20080487L NO 20080487 L NO20080487 L NO 20080487L NO 20080487 A NO20080487 A NO 20080487A NO 20080487 A NO20080487 A NO 20080487A NO 20080487 L NO20080487 L NO 20080487L
Authority
NO
Norway
Prior art keywords
ifnα2
mutants
present
ifna2
recombinant
Prior art date
Application number
NO20080487A
Other languages
English (en)
Inventor
Gideon Schreiber
Laila C Roisman
Diego Jaitin
Eyal Kalie
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO20080487L publication Critical patent/NO20080487L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SAMMENDRAG Den foreliggende oppfinnelsen tilveiebringer IFNa2-mutanter og aktive fragmenter, analoger, derivater og varianter av disse som har bedret spesifikk agonist- eller antagonistaktivitet sammenlignet med villtype IFNa2. Den foreliggende oppfinnelsen tilveiebringer videre farmasøytiske sammensetninger som omfatter IFNa2-mutanter som kan brukes for å behandle eller forebygge kreft, autoimmune sykdommer, infeksjonssykdommer eller lidelser assosiert med forhøyet ekspresjon av IFNa2.
NO20080487A 2005-06-29 2008-01-25 Rekominant interferona2 (IFNa2) mutanter NO20080487L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69481005P 2005-06-29 2005-06-29
PCT/IL2006/000754 WO2007000769A2 (en) 2005-06-29 2006-06-28 RECOMBINANT INTERFERON α2 (IFNα2) MUTANTS

Publications (1)

Publication Number Publication Date
NO20080487L true NO20080487L (no) 2008-03-28

Family

ID=37595529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080487A NO20080487L (no) 2005-06-29 2008-01-25 Rekominant interferona2 (IFNa2) mutanter

Country Status (12)

Country Link
US (2) US7767799B2 (no)
EP (2) EP2476428B1 (no)
JP (1) JP5208733B2 (no)
CN (1) CN101304758B (no)
AU (1) AU2006263331B2 (no)
BR (1) BRPI0613098A2 (no)
CA (1) CA2613737C (no)
EA (1) EA014157B1 (no)
ES (2) ES2435846T3 (no)
HK (1) HK1125317A1 (no)
NO (1) NO20080487L (no)
WO (1) WO2007000769A2 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
KR101759460B1 (ko) 2007-09-21 2017-07-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함
WO2010030671A1 (en) * 2008-09-09 2010-03-18 University Of Medicine And Dentistry Of New Jersey Type i interferon antagonists
US20120014911A1 (en) * 2009-01-09 2012-01-19 Serge Fuchs Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor
EA201700111A1 (ru) * 2011-10-28 2018-02-28 Тева Фармасьютикал Австралия Пти Лтд Полипептидные конструкции и их применение
CN102584956B (zh) * 2012-02-13 2014-09-17 中山大学 一种慢性乙型病毒性肝炎相关基因ifna2的新突变蛋白、编码基因及其应用
CN102532299B (zh) * 2012-02-23 2013-07-17 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
CN102532300B (zh) * 2012-02-23 2013-07-17 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
CN104470536A (zh) 2012-03-03 2015-03-25 免疫基因公司 工程化的抗体-干扰素突变体融合分子
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US20150366944A1 (en) 2013-02-20 2015-12-24 Yeda Research And Development Co. Ltd. Interferon treatment targeting mutant p53 expressing cells
PL2992013T3 (pl) 2013-04-29 2020-09-07 Teva Pharmaceuticals Australia Pty Ltd Przeciwciała anty-cd38 i fuzje z atenuowanym interferonem alfa-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
SG11201600165WA (en) * 2013-07-19 2016-02-26 Vib Vzw Targeting of cytokine antagonists
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
CN107556376B (zh) * 2017-09-08 2018-09-28 上海华新生物高技术有限公司 一种干扰素α-2b突变体及其制备方法和应用
CN108117595B (zh) * 2018-02-28 2020-06-26 中国科学院微生物研究所 一种犬α干扰素的制备及其应用
CN108752457B (zh) * 2018-05-23 2019-06-21 华中农业大学 一种来源于草鱼干扰素的衍生多肽及其应用
CN108997489B (zh) * 2018-09-04 2021-08-27 中国药科大学 干扰素突变体及干扰素突变体融合抗体及其制备方法、应用
CN110437328B (zh) * 2019-08-22 2021-06-04 安阳工学院 一种猪干扰素α突变体YNS及其制备方法和应用
AR117715A1 (es) * 2019-12-17 2021-08-25 Univ Nacional Del Litoral Unl Interferón hiperglicosilado con inmunogenicidad reducida
RU2741570C1 (ru) * 2019-12-26 2021-01-27 Генетик Диагностикс Энд Терапи 21 Лтд Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, несущий целевой ген, выбранный из группы генов IFNB1, IFNA14, IFNA2, IL12A, IL12B для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNB1, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNA14, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IFNA2, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL12A, или Escherichia coli JM110-NAS/GDTT1.8NAS12-IL12B, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора
CN113440603B (zh) * 2020-03-26 2022-07-08 复旦大学 人α干扰素亚型及受体结合相关位点突变体在制备防治新型冠状病毒感染药物中的用途
WO2023230231A1 (en) * 2022-05-25 2023-11-30 Malcolm Thomas Controlled expression of therapeutically relevant biomolecules for lumen-localized payloads in biomimetic nanovesicles and exosomes
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
ATE144149T1 (de) 1991-08-30 1996-11-15 Genentech Inc Therapeutisches verfahren zur behandlung von iddm
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
TW249202B (no) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
DK0859630T3 (da) 1995-10-04 2003-03-24 Schering Corp Kombination af termozolomid og alfa-IFN til behandling af fremskreden cancer
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
WO1999003887A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US20040002474A1 (en) 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
DE60120917T2 (de) 2000-01-26 2007-01-25 Schering Corp. Kombinationspräparat zur krebstherapie
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
JP5424521B2 (ja) * 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
AU2003267700A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2004031352A2 (en) * 2002-10-01 2004-04-15 Xencor, Inc. Interferon variants with improved properties
AU2004213565A1 (en) 2003-02-18 2004-09-02 Merck Patent Gmbh Fusion proteins of interferon alpha muteins with improved properties
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
US20050008616A1 (en) 2003-07-11 2005-01-13 Schering Aktiengesellschaft Recombinant human interferon-beta-1b polypeptides
EP1789074A4 (en) 2004-08-09 2009-08-12 Alios Biopharma Inc PROTEASE-RESISTANT HYPERGLYCOSYL SYNTHETIC POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME

Also Published As

Publication number Publication date
ES2435846T3 (es) 2013-12-23
US20080166319A1 (en) 2008-07-10
EP1909822A2 (en) 2008-04-16
EP2476428A1 (en) 2012-07-18
EP2476428B1 (en) 2013-08-21
WO2007000769A3 (en) 2009-05-22
CA2613737C (en) 2017-05-23
JP5208733B2 (ja) 2013-06-12
EA200800159A1 (ru) 2008-10-30
CN101304758B (zh) 2013-08-21
ES2436761T3 (es) 2014-01-07
US20080279823A1 (en) 2008-11-13
AU2006263331A1 (en) 2007-01-04
US7767799B2 (en) 2010-08-03
EP1909822B1 (en) 2013-09-25
HK1125317A1 (en) 2009-08-07
EA014157B1 (ru) 2010-10-29
EP1909822A4 (en) 2009-12-02
JP2009501514A (ja) 2009-01-22
AU2006263331B2 (en) 2012-02-16
CA2613737A1 (en) 2007-01-04
US7919078B2 (en) 2011-04-05
CN101304758A (zh) 2008-11-12
BRPI0613098A2 (pt) 2010-12-21
WO2007000769A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
NO20080487L (no) Rekominant interferona2 (IFNa2) mutanter
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
WO2013049770A3 (en) Methods of treating cancer
EA202190661A1 (ru) Агонисты фарнезоидного х-рецептора для лечения заболевания
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MX2009005398A (es) Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
DE602005021696D1 (de) Indazolcarbonsäureamidverbindungen
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
DK1957484T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
ATE431824T1 (de) Chinolinon-carboxamid-verbindungen
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
NO341523B1 (no) Benzoimidazol-2-ylpyrimidiner og -pyraziner som modulatorer av histamin H4-reseptoren, farmasøytisk sammensetning samt anvendelse
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application